Apollomics, Inc. (APLM) Stock Score, Valuation & Financial Research
Apollomics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 31/100.
Quick answer for APLM
Apollomics, Inc. currently has a Wall Street Score of 31/100. The stored market price is $23.21. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Apollomics, Inc. does
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollom
APLM financial snapshot
- Wall Street Score:
- 31/100
- Current price:
- $23.21
- Market capitalization:
- $51.0M
- Revenue:
- $8.7M
- Net income:
- $-64.8M
- Free cash flow:
- $-10.4M
- Cash:
- $3.3M
- Total debt:
- $643K
- EPS:
- -62.05
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 24/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $-10.4M, showing cash burn in the current stored period.
- The balance sheet shows $3.3M of cash versus $643K of total debt, leaving more cash than debt.
- The current research record carries a missing opportunity history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research APLM
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.